Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
Nakashima K, Aoshima M, Ohfuji S, Yamawaki S, Nemoto M, Hasegawa S, Noma S, Misawa M, Hosokawa N, Yaegashi M, Otsuka Y. Nakashima K, et al. Among authors: aoshima m. Hum Vaccin Immunother. 2018;14(8):1923-1930. doi: 10.1080/21645515.2018.1455476. Epub 2018 May 14. Hum Vaccin Immunother. 2018. PMID: 29561248 Free PMC article. Clinical Trial.
Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K. Sando E, et al. Among authors: aoshima m. Vaccine. 2019 May 6;37(20):2687-2693. doi: 10.1016/j.vaccine.2019.04.009. Epub 2019 Apr 8. Vaccine. 2019. PMID: 30975569
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.
Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, Morimoto K; Adult Pneumonia Study Group-Japan (APSG-J). Suzuki M, et al. Among authors: aoshima m. Lancet Infect Dis. 2017 Mar;17(3):313-321. doi: 10.1016/S1473-3099(17)30049-X. Epub 2017 Jan 24. Lancet Infect Dis. 2017. PMID: 28126327
Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study.
Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, Misawa M, Otsuka Y, Motojima S. Nakashima K, et al. Among authors: aoshima m. J Microbiol Immunol Infect. 2018 Dec;51(6):810-820. doi: 10.1016/j.jmii.2017.07.007. Epub 2017 Jul 23. J Microbiol Immunol Infect. 2018. PMID: 28779879 Free article.
Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
Maeda H, Gopal Dhoubhadel B, Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K. Maeda H, et al. Among authors: aoshima m. Vaccine. 2022 Sep 2;40(37):5504-5512. doi: 10.1016/j.vaccine.2022.07.041. Epub 2022 Aug 10. Vaccine. 2022. PMID: 35963821
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K, Suzuki K, Aoshima M, Murabata M, Kondo K, Ohfuji S, Fukushima W, Maeda A, Hirota Y; Pneumonia in Elderly People Study Group. Nakashima K, et al. Among authors: aoshima m. Vaccine. 2022 Nov 2;40(46):6589-6598. doi: 10.1016/j.vaccine.2022.09.055. Epub 2022 Sep 30. Vaccine. 2022. PMID: 36184405 Free article.
258 results